Forge Genetics

Investor: AbbVie

Forge Genetics has secured a licensing agreement with global pharmaceutical company AbbVie for its genome editing technology. Summary of transaction details: Value: N/A Sector: Pharmaceutical Advisor: N/A Key Entities: Forge Genetics, AbbVie Location: East Midlands Note: The partnership follows successful proof-of-concept work where Forge Genetics' technology demonstrated its potential in a limited field.

Investor: Midlands Engine Investment Fund II, Mercia Ventures